1. Home
  2. LPTH vs ANL Comparison

LPTH vs ANL Comparison

Compare LPTH & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LightPath Technologies Inc.

LPTH

LightPath Technologies Inc.

HOLD

Current Price

$9.82

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$16.06

Market Cap

998.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPTH
ANL
Founded
1985
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
998.8M
IPO Year
2011
2022

Fundamental Metrics

Financial Performance
Metric
LPTH
ANL
Price
$9.82
$16.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$13.33
$20.00
AVG Volume (30 Days)
3.4M
151.1K
Earning Date
05-14-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$37,202,630.00
N/A
Revenue This Year
$83.04
$36.02
Revenue Next Year
$24.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.26
N/A
52 Week Low
$5.83
$0.88
52 Week High
$18.94
$17.25

Technical Indicators

Market Signals
Indicator
LPTH
ANL
Relative Strength Index (RSI) 44.13 N/A
Support Level $8.96 N/A
Resistance Level $10.96 N/A
Average True Range (ATR) 0.58 0.00
MACD 0.10 0.00
Stochastic Oscillator 56.64 0.00

Price Performance

Historical Comparison
LPTH
ANL

About LPTH LightPath Technologies Inc.

LightPath Technologies Inc manufactures, distributes, and integrates proprietary optical components and assemblies. It develops optical solutions for traditional optics and communications markets. The company's products include precision molded optics and infrared products, serving markets such as distribution, laser, industrial, instrumentation, telecommunications, and defense. Its products are categorized as infrared components, visible components, assemblies and modules, and engineering services. G5 Infrared's revenue mainly comes from infrared components and assemblies.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: